Welcome to our dedicated page for Aveanna Healthcare Holdings SEC filings (Ticker: AVAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aveanna Healthcare Holdings Inc. filings document the public-company disclosures of a home healthcare operator with pediatric and adult care services. Its 8-K reports cover operating and financial results, guidance updates, Regulation FD investor presentations, material-event disclosures, capital-structure matters, and material agreements tied to the company and its common stock.
Proxy and governance filings describe annual meeting matters, board composition, committee service, executive compensation arrangements, employment agreements, stock incentive plan matters, and stockholders agreement provisions, including transfer restrictions and ownership-guideline-related terms. The filing record also includes director transitions and governance disclosures connected to compensation, nominating and corporate governance, and clinical quality and compliance oversight.
Aveanna Healthcare (AVAH): insider sale reported. A reporting person affiliated with J.H. Whitney disclosed that J.H. Whitney VII, L.P. sold 8,346,059 shares of Aveanna common stock at $9 per share on 10/21/2025 in an underwritten secondary offering.
Following the transaction, 20,544,696 shares were reported as beneficially owned indirectly by J.H. Whitney VII, L.P. Additional indirect holdings were listed as 15,523,809 shares by PSA Healthcare Investment Holdings LLC and 1,426,034 shares by PSA Iliad Holdings LLC. The filing notes shared voting and dispositive power across related entities as described in the ownership structure.
Aveanna Healthcare Holdings Inc. announced a secondary offering by selling stockholders of 10,000,000 shares of common stock at $9.00 per share. The company will not receive any proceeds from these sales; proceeds go to the selling stockholders. Underwriters have a 30‑day option to purchase up to 1,500,000 additional shares.
The pricing implies an aggregate public offering of $90,000,000, with underwriting discounts of $4,050,000 and proceeds to selling stockholders of $85,950,000. Aveanna’s common stock trades on Nasdaq as AVAH. Shares outstanding were 208,259,393 as of June 28, 2025.
Aveanna also provided preliminary, unaudited Q3 results: revenue of $616–$624 million, net income of $11–$15 million, and Adjusted EBITDA of $77–$81 million, each described as growth over the prior year’s third quarter. Delivery of shares is expected on or about October 23, 2025.
Aveanna Healthcare Holdings (AVAH) announced a secondary offering in which the Selling Stockholders are offering 10,000,000 shares of common stock. The company stated it will not receive any proceeds from these sales. The underwriters have a 30‑day option to purchase up to 1,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The company included a preliminary third‑quarter update: revenue is expected at $616–$624 million (up 21.0%–22.6% year over year), net income at $11–$15 million (up 125.7%–135.0%), and Adjusted EBITDA at $77–$81 million (up 61.0%–69.3%). These figures are unaudited and subject to completion of financial closing procedures. A 90‑day lock‑up applies to the company, Selling Stockholders, directors and officers, subject to customary exceptions.
Shares outstanding were 208,911,373 as of October 15, 2025; this is a baseline figure, not the amount being offered.
Aveanna Healthcare Holdings (AVAH) announced a secondary offering in which the Selling Stockholders are offering 10,000,000 shares of common stock. The company stated it will not receive any proceeds from these sales. The underwriters have a 30‑day option to purchase up to 1,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The company included a preliminary third‑quarter update: revenue is expected at $616–$624 million (up 21.0%–22.6% year over year), net income at $11–$15 million (up 125.7%–135.0%), and Adjusted EBITDA at $77–$81 million (up 61.0%–69.3%). These figures are unaudited and subject to completion of financial closing procedures. A 90‑day lock‑up applies to the company, Selling Stockholders, directors and officers, subject to customary exceptions.
Shares outstanding were 208,911,373 as of October 15, 2025; this is a baseline figure, not the amount being offered.
Aveanna Healthcare Holdings (AVAH) announced a secondary offering in which the Selling Stockholders are offering 10,000,000 shares of common stock. The company stated it will not receive any proceeds from these sales. The underwriters have a 30‑day option to purchase up to 1,500,000 additional shares at the public offering price, less underwriting discounts and commissions.
The company included a preliminary third‑quarter update: revenue is expected at $616–$624 million (up 21.0%–22.6% year over year), net income at $11–$15 million (up 125.7%–135.0%), and Adjusted EBITDA at $77–$81 million (up 61.0%–69.3%). These figures are unaudited and subject to completion of financial closing procedures. A 90‑day lock‑up applies to the company, Selling Stockholders, directors and officers, subject to customary exceptions.
Shares outstanding were 208,911,373 as of October 15, 2025; this is a baseline figure, not the amount being offered.
Aveanna Healthcare Holdings Inc. furnished an 8-K to announce it issued a press release with preliminary results for the three-month period ended September 27, 2025. The press release, dated October 21, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02 is “furnished” and not “filed” under the Exchange Act, and will only be incorporated by reference into other filings if specifically stated.
Aveanna Healthcare Holdings Inc. furnished an 8-K to announce it issued a press release with preliminary results for the three-month period ended September 27, 2025. The press release, dated October 21, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02 is “furnished” and not “filed” under the Exchange Act, and will only be incorporated by reference into other filings if specifically stated.
Aveanna Healthcare Holdings Inc. furnished an 8-K to announce it issued a press release with preliminary results for the three-month period ended September 27, 2025. The press release, dated October 21, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02 is “furnished” and not “filed” under the Exchange Act, and will only be incorporated by reference into other filings if specifically stated.
Aveanna Healthcare Holdings Inc. furnished an investor presentation as part of a current report. On September 29, 2025, the company made a financial presentation available to investors and attached it as Exhibit 99.1 to this report. The presentation is also accessible through the Investors section of Aveanna’s website.
The company explains that it routinely uses its website and investor presentations to share important and time-sensitive information. The materials in this report, including Exhibit 99.1, are designated as “furnished” rather than “filed,” which means they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other SEC filings unless specifically referenced.
Aveanna Healthcare Holdings Inc. amended its first-lien credit agreement through a refinancing and incremental debt transaction. The company’s subsidiary put in place new first-lien term loans totaling $1.325 billion and expanded its revolving credit commitments to $250 million, replacing the prior term and revolving facilities. The new revolving facility matures on September 17, 2030, and the new term loans mature on September 17, 2032, with 1% annual amortization and original issue discount of 99.75% of par.
The term loans and revolver bear interest at the borrower’s option at Term SOFR plus a margin of 3.75% or a base rate plus 2.75%, with potential margin step-downs based on first-lien net leverage. Aveanna used proceeds from the new term loans to fully refinance its existing first-lien term loans and repay its $415 million second-lien term loan, as well as to pay accrued interest and fund working capital and general corporate purposes.
Aveanna Healthcare Holdings Inc. amended its first-lien credit agreement through a refinancing and incremental debt transaction. The company’s subsidiary put in place new first-lien term loans totaling $1.325 billion and expanded its revolving credit commitments to $250 million, replacing the prior term and revolving facilities. The new revolving facility matures on September 17, 2030, and the new term loans mature on September 17, 2032, with 1% annual amortization and original issue discount of 99.75% of par.
The term loans and revolver bear interest at the borrower’s option at Term SOFR plus a margin of 3.75% or a base rate plus 2.75%, with potential margin step-downs based on first-lien net leverage. Aveanna used proceeds from the new term loans to fully refinance its existing first-lien term loans and repay its $415 million second-lien term loan, as well as to pay accrued interest and fund working capital and general corporate purposes.
Aveanna Healthcare Holdings Inc. Schedule 13G/A discloses significant ownership positions by several J.H. Whitney-related entities. J.H. Whitney VII, L.P. is reported as the beneficial owner of 28,890,755 shares (14.81%), and PSA Healthcare Investment Holdings LLC is reported as the beneficial owner of 15,588,583 shares (7.99%). Additional related entities report stakes of 1,443,143, 5,182,085, and 543,206 shares respectively.
The filing states the J.H. Whitney parties and Bain Capital-advised entities are bound by a Stockholders Agreement that requires them to vote for each other’s director nominees and coordinate transfers. The parties note that, based on available information, such a group could be deemed to beneficially own approximately 133,248,652 shares (≈68.302%), while the reporting persons disclaim beneficial ownership of each other’s shares and report sole voting and dispositive power over the shares they list.
On 8 Aug 2025 Aveanna Healthcare Holdings Inc. (AVAH) filed a Form 8-K under Item 7.01 (Regulation FD) to furnish an updated investor presentation (Exhibit 99.1). The deck is available in the “Investors” section of the company’s website and via IR e-mail alerts. Because the material is classified as “furnished,” it is not subject to Section 18 liability and will only be incorporated into other SEC filings if specifically referenced. Aveanna reiterates that its website is a primary channel for time-critical disclosures.
- No financial statements, earnings metrics or major transactions accompany this report.
- The 8-K is informational only and has no immediate accounting or voting impact.